Free shipping on all orders over $ 500


Cat. No. M3768
Ixabepilone Structure

Ixempra, BMS-247550, NSC 710428

Size Price Availability Quantity
5mg USD 300 In stock
10mg USD 480 In stock
50mg USD 1920 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

Ixabepilone (BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound. Ixabepilone induces cell cycle arrest at the G(2)-M phase transition and subsequent apoptotic cell death of MDA-MB-468 (468) cells. Ixabepilone, on a once every 21-day schedule, is modestly active against metastatic gastric cancer previously treated with a taxane. The days 1-5 every 21 days schedule had a more favorable safety profile but no activity. The results of this study suggest that once every 21-day ixabepilone schedule should be pursued further in untreated gastric or gastroesophageal adenocarcinoma patients. Ixabepilone has demonstrated activity in patients with chemotherapy-naive metastatic HRPC. Major toxicities were neutropenia and neuropathy. Further testing to define its activity relative to standard therapy is warranted.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 506.7
Formula C27H42N2O5S
CAS Number 219989-84-1
Purity >98%
Solubility DMSO
Storage at -20°C

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.
Kim YH, et al. Cancer Chemother Pharmacol. 2012 Oct;70(4):583-90. PMID: 22886073.

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Roché H, et al. Clin Breast Cancer. 2012 Jun;12(3):167-74. PMID: 22607766.

A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
Huang H, et al. Clin Cancer Res. 2010 Mar 1;16(5):1634-41. PMID: 20179242.

Related Microtubule Products

DM4, a chemical derivative of maytansine, is a potent and selective cytotoxic agent that inhibit cell division.


VcMMAE is a anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).


Crolibulin (also known as EPC2407 and crinobulin) is a small molecule tubulin polymerization inhibitor with potential antineoplastic activity.


Maytansinol, also known as Ansamitocin P-0, is a potent microtubule depolymerizing agent.


BTB-1 is a selective and ATP-competitive Kif18A inhibitor, with IC50 value of 1.69 μM.

Abmole Inhibitor Catalog 2017

Keywords: Ixabepilone, Ixempra, BMS-247550, NSC 710428 supplier, Microtubule, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.